Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide

American Journal of Gastroenterology

Volumn 94, Issue 1, 1999, Pages 278-279

  Raderer, Markus ^a   Hejna, Michael H L ^a   Kurtaran, Amir ^b   Kornek, Gabriela V ^a   Valencak, Julia B ^a   Oberhuber, Georg ^a   Vorbeck, Friedrich ^a   Virgolini, Irene ^b   Scheithauer, Werner ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CASE REPORT; HUMAN; LAPAROTOMY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY; TREATMENT INDICATION;

EID: 0032922248     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.00821.x     Document Type: Article

References (10)

1. Cook G.G. Hepatocellular carcinoma One of the world's most common malignancies . Q J Med. 233:1985;705-708.
2. Venook A.P. Treatment of hepatocellular carcinoma Too many options? J Clin Oncol. 12:1994;1323-1334.
3. Lotze M., Flickinger J., Carr B. Hepatobiliary neoplasms. DeVita V., Hellman S., Rosenberg S.A. Cancer Principles and practice of oncology (4th edition) . 1989;883-914 Lippincott Co, Philadelphia.
4. Cascinu S., Del Ferro E., Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer. 71:1995;97-101.
5. Edmondson H.A., Steiner P.E. Primary carcinoma of the liver. A study of 100 cases among 48900 autopsies. Cancer. 7:1954;462-503.
6. Buscail L., Saint-Laurent N., Chastre E., et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56:1996;1823-1827.
7. Janson E.T., Gobl A., Kalkner K.M., Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res. 56:1996;2561-2565.
8. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. Intramuscular injections of slow release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 132:1995;320-325.
9. Harrison S.M., Barnard R., Ho K.Y., Rajkovic I., Waters M.J. Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptor. Endocrinology. 136:1995;651-659.
10. Ren S.G., Ezzat S., Melmed S., Braunstein G.D. Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology. 131:1992;2479-2481.